Literature DB >> 26438489

Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.

Anuradha Chowdhary1, Pradeep Kumar Singh2, Shallu Kathuria2, Ferry Hagen3, Jacques F Meis4.   

Abstract

We compared EUCAST and CLSI antifungal susceptibility testing (AFST) methods for triazoles and amphotericin B against 124 clinical Mucorales isolates. The EUCAST method yielded MIC values 1- to 3-fold dilutions higher than those of the CLSI method for amphotericin B. The essential agreements between the two methods for triazoles were high, i.e., 99.1% (voriconazole), 98.3% (isavuconazole), and 87% (posaconazole), whereas it was significantly lower for amphotericin B (66.1%). Strategies for harmonization of the two methods for Mucorales AFST are warranted.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26438489      PMCID： PMC4649204          DOI： 10.1128/AAC.02107-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Authors:  Roxana G Vitale; G Sybren de Hoog; Patrick Schwarz; Eric Dannaoui; Shuwen Deng; Marie Machouart; Kerstin Voigt; Wendy W J van de Sande; Somayeh Dolatabadi; Jacques F Meis; Grit Walther
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

3.  In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.

Authors:  P E Verweij; G M González; N P Wiedrhold; C Lass-Flörl; P Warn; M Heep; M A Ghannoum; J Guinea
Journal:  J Chemother       Date:  2009-06       Impact factor: 1.714

4.  Isavuconazole treatment of a patient with disseminated mucormycosis.

Authors:  Driele Peixoto; Lisa S Gagne; Sarah P Hammond; Erin T Gilmore; Amy C Joyce; Robert J Soiffer; Francisco M Marty
Journal:  J Clin Microbiol       Date:  2014-01-08       Impact factor: 5.948

Review 5.  Healthcare-associated outbreaks due to Mucorales and other uncommon fungi.

Authors:  Setareh Davoudi; Linda S Graviss; Dimitrios P Kontoyiannis
Journal:  Eur J Clin Invest       Date:  2015-07       Impact factor: 4.686

Review 6.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

7.  Development of new strategies for early diagnosis of mucormycosis from bench to bedside.

Authors:  Thomas J Walsh; Anna Skiada; Oliver A Cornely; Emmanuel Roilides; Ashraf Ibrahim; Theoklis Zaoutis; Andreas Groll; Olivier Lortholary; Dimitrios P Kontoyiannis; George Petrikkos
Journal:  Mycoses       Date:  2014-12       Impact factor: 4.377

Review 8.  Mucormycosis treated with posaconazole: review of 96 case reports.

Authors:  Joerg J Vehreschild; Andrea Birtel; Maria J G T Vehreschild; Blasius Liss; Fedja Farowski; Matthias Kochanek; Michal Sieniawski; Angela Steinbach; Kerstin Wahlers; Gerd Fätkenheuer; Oliver A Cornely
Journal:  Crit Rev Microbiol       Date:  2012-08-24       Impact factor: 7.624

Review 9.  Our 2014 approach to mucormycosis.

Authors:  Daniela Tacke; Philipp Koehler; Birgid Markiefka; Oliver A Cornely
Journal:  Mycoses       Date:  2014-05-15       Impact factor: 4.377

10.  Analysis of a food-borne fungal pathogen outbreak: virulence and genome of a Mucor circinelloides isolate from yogurt.

Authors:  Soo Chan Lee; R Blake Billmyre; Alicia Li; Sandra Carson; Sean M Sykes; Eun Young Huh; Piotr Mieczkowski; Dennis C Ko; Christina A Cuomo; Joseph Heitman
Journal:  MBio       Date:  2014-07-08       Impact factor: 7.867
View more
  15 in total

1.  A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles.

Authors:  Lysett Wagner; Sybren de Hoog; Ana Alastruey-Izquierdo; Kerstin Voigt; Oliver Kurzai; Grit Walther
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems.

Authors:  Nicolas Pellaton; Dominique Sanglard; Frederic Lamoth; Alix T Coste
Journal:  Front Cell Infect Microbiol       Date:  2022-05-04       Impact factor: 6.073

3.  Combat trauma-related invasive fungal wound infections.

Authors:  David R Tribble; Anuradha Ganesan; Carlos J Rodriguez
Journal:  Curr Fungal Infect Rep       Date:  2020-04-16

Review 4.  Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.

Authors:  Suganthini Krishnan Natesan; Pranatharthi H Chandrasekar
Journal:  Infect Drug Resist       Date:  2016-12-07       Impact factor: 4.003

5.  In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories.

Authors:  Michael A Pfaller; Paul R Rhomberg; Nathan P Wiederhold; Connie Gibas; Carmita Sanders; Hongxin Fan; James Mele; Laura L Kovanda; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 6.  Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Authors:  Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann; Bart J A Rijnders; Andreas H Groll; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

7.  Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.

Authors:  Hamid Badali; Connie Cañete-Gibas; Dora McCarthy; Hoja Patterson; Carmita Sanders; Marjorie P David; James Mele; Hongxin Fan; Nathan P Wiederhold
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

Review 8.  Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.

Authors:  Derry K Mercer; Marcelo D T Torres; Searle S Duay; Emma Lovie; Laura Simpson; Maren von Köckritz-Blickwede; Cesar de la Fuente-Nunez; Deborah A O'Neil; Alfredo M Angeles-Boza
Journal:  Front Cell Infect Microbiol       Date:  2020-07-07       Impact factor: 5.293

9.  High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Authors:  Alexander F A D Schauwvlieghe; Jochem B Buil; Paul E Verweij; Rogier A S Hoek; Jan J Cornelissen; Nicole M A Blijlevens; Stefanie S V Henriet; Bart J A Rijnders; Roger J M Brüggemann
Journal:  Mycoses       Date:  2019-12-15       Impact factor: 4.377

Review 10.  Genes, Pathways, and Mechanisms Involved in the Virulence of Mucorales.

Authors:  Carlos Lax; Carlos Pérez-Arques; María Isabel Navarro-Mendoza; José Tomás Cánovas-Márquez; Ghizlane Tahiri; José Antonio Pérez-Ruiz; Macario Osorio-Concepción; Laura Murcia-Flores; Eusebio Navarro; Victoriano Garre; Francisco Esteban Nicolás
Journal:  Genes (Basel)       Date:  2020-03-16       Impact factor: 4.096
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.